FWM
ABBV icon

Focused Wealth Management’s AbbVie ABBV Stock Holding History

Focused Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,000
Closed -$592K – 187
2024
Q3 		$592K Buy
+3,000
New +$560K 0.08% 91

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Focused Wealth Management's ABBV Position: Q1 2026 in Review

Focused Wealth Management increased its AbbVie (ABBV) stake by 9.3% in Q1 2026, buying an estimated $176K and bringing the position to 9,362 shares worth $2.04M. The position accounts for 0.21% of the portfolio, ranked #52.

Focused Wealth Management first reported a position in ABBV in Q3 2013 and has held it in 51 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Focused Wealth Management held 9,362 shares of AbbVie worth $2.04M as of Q1 2026.
  • Focused Wealth Management bought 793 AbbVie shares in Q1 2026, an estimated $176K.
  • AbbVie made up 0.21% of Focused Wealth Management's portfolio in Q1 2026, its #52 holding.
  • Focused Wealth Management first reported a position in AbbVie in Q3 2013 and has held it in 51 quarters since.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Focused Wealth Management's 13F filing for Q1 2026, filed 20 Apr 2026.